Comparative Pharmacology
Head-to-head clinical analysis: ESTRADIOL AND NORETHINDRONE ACETATE versus PROMETRIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTRADIOL AND NORETHINDRONE ACETATE versus PROMETRIUM.
ESTRADIOL AND NORETHINDRONE ACETATE vs PROMETRIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol is an estrogen that binds to estrogen receptors (ERα/ERβ) to regulate gene transcription involved in reproductive and non-reproductive tissues. Norethindrone acetate is a progestin that binds to progesterone receptors, inducing secretory endometrium and inhibiting gonadotropin secretion.
Progesterone binds to progesterone receptors in target tissues, promoting endometrial maturation, reducing uterine contractility, and suppressing ovulation.
1 tablet (estradiol 1 mg / norethindrone acetate 0.5 mg) orally once daily; adjust dose based on response and tolerability.
Oral: 200 mg once daily at bedtime for 12 consecutive days per 28-day cycle in combination with conjugated estrogens 0.625 mg daily. For secondary amenorrhea: 400 mg once daily at bedtime for 10 days. Intravaginal: 4% gel (90 mg) or 8% gel (180 mg) applied every other day for 6 doses in postmenopausal women with intact uterus on estrogen therapy.
None Documented
None Documented
Estradiol: terminal ~12-14 hours; norethindrone acetate: terminal ~8-11 hours. Steady-state reached within 5-7 days.
Terminal half-life: Approximately 16-18 hours for oral micronized progesterone (Prometrium); permits twice-daily dosing for luteal phase support.
Estradiol: primarily renal as metabolites (glucuronide and sulfate conjugates), ~90% in urine, ~10% in feces as bile. Norethindrone: urinary (50-70% as metabolites) and fecal (20-30%).
Urine (50-60% as metabolites, <1% unchanged); feces (20-30% as metabolites); minor biliary elimination.
Category D/X
Category C
Progestin
Progestin